BR112022024760A2 - Métodos de tratamento do complexo de esclerose tuberosa - Google Patents
Métodos de tratamento do complexo de esclerose tuberosaInfo
- Publication number
- BR112022024760A2 BR112022024760A2 BR112022024760A BR112022024760A BR112022024760A2 BR 112022024760 A2 BR112022024760 A2 BR 112022024760A2 BR 112022024760 A BR112022024760 A BR 112022024760A BR 112022024760 A BR112022024760 A BR 112022024760A BR 112022024760 A2 BR112022024760 A2 BR 112022024760A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- tuberous sclerosis
- treatment
- sclerosis complex
- individual
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Preparation Of Fruits And Vegetables (AREA)
- Medicinal Preparation (AREA)
Abstract
MÉTODOS DE TRATAMENTO DO COMPLEXO DE ESCLEROSE TUBEROSA. A presente invenção refere-se a métodos de tratamento do complexo de esclerose tuberosa em um indivíduo que precisa do mesmo ao administrar ao indivíduo composições que compreendem um modulador alostérico negativo (NAM) de mGlu5 que tem a estrutura de Fórmula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063035313P | 2020-06-05 | 2020-06-05 | |
PCT/EP2021/065075 WO2021245281A1 (en) | 2020-06-05 | 2021-06-04 | Methods of treatment of tuberous sclerosis complex |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022024760A2 true BR112022024760A2 (pt) | 2023-03-07 |
Family
ID=76325558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022024760A BR112022024760A2 (pt) | 2020-06-05 | 2021-06-04 | Métodos de tratamento do complexo de esclerose tuberosa |
Country Status (12)
Country | Link |
---|---|
US (2) | US11684613B2 (pt) |
EP (1) | EP4161512A1 (pt) |
JP (1) | JP2023528895A (pt) |
KR (1) | KR20230027145A (pt) |
CN (1) | CN116056701A (pt) |
AU (1) | AU2021285273A1 (pt) |
BR (1) | BR112022024760A2 (pt) |
CA (1) | CA3180794A1 (pt) |
CL (1) | CL2022003435A1 (pt) |
IL (1) | IL298709A (pt) |
MX (1) | MX2022015407A (pt) |
WO (1) | WO2021245281A1 (pt) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA80888C2 (en) | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
JP4690395B2 (ja) | 2004-06-01 | 2011-06-01 | エフ.ホフマン−ラ ロシュ アーゲー | mGlu5レセプターアンタゴニストとしてのピリジン−4−エチニル−イミダゾール及びピラゾール |
BRPI0720954A2 (pt) | 2006-12-21 | 2014-03-18 | Hoffmann La Roche | Polimorfos de um antagonista de receptor mglur5 |
US8211882B2 (en) | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
US20120039999A1 (en) | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
-
2021
- 2021-06-04 MX MX2022015407A patent/MX2022015407A/es unknown
- 2021-06-04 KR KR1020237000370A patent/KR20230027145A/ko active Search and Examination
- 2021-06-04 EP EP21730918.6A patent/EP4161512A1/en active Pending
- 2021-06-04 IL IL298709A patent/IL298709A/en unknown
- 2021-06-04 CA CA3180794A patent/CA3180794A1/en active Pending
- 2021-06-04 BR BR112022024760A patent/BR112022024760A2/pt unknown
- 2021-06-04 JP JP2022574675A patent/JP2023528895A/ja active Pending
- 2021-06-04 AU AU2021285273A patent/AU2021285273A1/en active Pending
- 2021-06-04 CN CN202180057592.9A patent/CN116056701A/zh active Pending
- 2021-06-04 WO PCT/EP2021/065075 patent/WO2021245281A1/en unknown
-
2022
- 2022-12-02 US US18/061,239 patent/US11684613B2/en active Active
- 2022-12-05 CL CL2022003435A patent/CL2022003435A1/es unknown
-
2023
- 2023-05-11 US US18/315,723 patent/US11998535B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11684613B2 (en) | 2023-06-27 |
EP4161512A1 (en) | 2023-04-12 |
AU2021285273A1 (en) | 2023-01-19 |
WO2021245281A1 (en) | 2021-12-09 |
MX2022015407A (es) | 2023-05-16 |
CL2022003435A1 (es) | 2023-10-20 |
US20230100520A1 (en) | 2023-03-30 |
US11998535B2 (en) | 2024-06-04 |
KR20230027145A (ko) | 2023-02-27 |
JP2023528895A (ja) | 2023-07-06 |
US20230277513A1 (en) | 2023-09-07 |
CA3180794A1 (en) | 2021-12-09 |
CN116056701A (zh) | 2023-05-02 |
IL298709A (en) | 2023-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018003161A (es) | Metodos para tratar infecciones por virus arenaviridae y coronaviridae. | |
WO2018100558A8 (en) | Cyclic dinucleotides as sting (stimulator of interferon genes) agonists | |
BR112022012594A2 (pt) | Dosagem de gama-hidroxibutirato (ghb) | |
BR112015022765A2 (pt) | composição biocida e processo de tratamento da água ou de superfícies em contato com água | |
MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
CL2020003276A1 (es) | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias | |
MX2019013561A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
SG11201811536PA (en) | Composition for removing sulfur-containing compound | |
BR112021018924A2 (pt) | Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento | |
UA117673C2 (uk) | Поліміксини, композиція, спосіб одержання і спосіб застосування (варіанти) | |
BR112022020291A2 (pt) | Inibidores de cd38 | |
ZA202201364B (en) | Deuterated compounds for use in the treatment of cancer | |
EA201891808A1 (ru) | Трис-амидные соединения и композиции, содержащие их | |
EA201991988A1 (ru) | Композиции и способы для способствования росту волос с помощью ингибиторов mpc1 | |
MX2021015673A (es) | Alteracion de biopelicula. | |
ECSP22026478A (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
BR112023001861A2 (pt) | Composições e métodos para tratamento de doenças e distúrbios | |
BR112022024760A2 (pt) | Métodos de tratamento do complexo de esclerose tuberosa | |
BR112016002643A2 (pt) | composição para tratamento de pele e método para produção de uma composição para tratamento de pele | |
NI202100055A (es) | Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéutica del mismo. | |
BR112018007505A2 (pt) | processo industrial para a preparação de sal de (e)-3-carboxiacrilato de (5s,10s)-10-benzil-16-metil-11,14,18-trioxo-15,17,19-trioxa-2,7,8-tritia-12-aza-henicosan-5-amínio | |
BR112018015044A2 (pt) | formulação de cuidados pessoais, e método de umedecimento da pele ou dos cabelos em pacientes | |
BR112023001621A2 (pt) | Métodos de tratamento de neuralgia trigeminal | |
RU2014123690A (ru) | Терапевтическое средство при артрозе | |
BR112023022298A2 (pt) | Moduladores de trex1 |